Literature DB >> 18332897

Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Shi Fang Yan1, Ravichandran Ramasamy, Ann Marie Schmidt.   

Abstract

Many important biochemical mechanisms are activated in the presence of high levels of glucose, which occur in diabetes. Elevated levels of glucose accelerate the formation of advanced glycation end-products (AGEs). Via their chief signaling receptor-the AGE-specific receptor (commonly abbreviated as RAGE)-AGEs generate reactive oxygen species and activate inflammatory signaling cascades. Consequently, AGEs have key roles in the pathogenesis of diabetic complications. Two discoveries have advanced our knowledge of the roles of RAGE in inflammation. First, this receptor has multiple ligands and binds not only AGEs but also proinflammatory, calcium-binding S100 proteins (also known as calgranulins) and nuclear high mobility group protein box-1. Second, RAGE is expressed on T lymphocytes, monocytes and macrophages; RAGE expression on T lymphocytes is essential for effective priming of immune responses in vivo. In this Review, we chronicle roles for RAGE in the pathogenesis of diabetic complications and develop the hypothesis that, in addition to RAGE's central role in the inflammatory response, it is critically linked to the pathogenesis of types 1 and 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332897     DOI: 10.1038/ncpendmet0786

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  135 in total

1.  Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.

Authors:  Mohamed A Abdelmegeed; Atrayee Banerjee; Seong-Ho Yoo; Sehwan Jang; Frank J Gonzalez; Byoung-Joon Song
Journal:  J Hepatol       Date:  2012-06-02       Impact factor: 25.083

Review 2.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 3.  Vascular Smooth Muscle as a Target for Novel Therapeutics.

Authors:  Karen E Porter; Kirsten Riches
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

Review 4.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

5.  The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.

Authors:  Ishwarlal Jialal; Harmeet Kaur
Journal:  Curr Diab Rep       Date:  2012-02-08       Impact factor: 4.810

6.  Arterial calcification is driven by RAGE in Enpp1-/- mice.

Authors:  Denise L Cecil; Robert A Terkeltaub
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

7.  Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation.

Authors:  Li Meng; Jehyun Park; Qiangjun Cai; Linda Lanting; Marpadga A Reddy; Rama Natarajan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

Review 8.  A new perspective on mechanisms governing skeletal complications in type 1 diabetes.

Authors:  Zeynep Seref-Ferlengez; Sylvia O Suadicani; Mia M Thi
Journal:  Ann N Y Acad Sci       Date:  2016-08-29       Impact factor: 5.691

9.  Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.

Authors:  Arthur C K Chung; Haiyan Zhang; Yao-Zhong Kong; Jia-Ju Tan; Xiao R Huang; Jeffrey B Kopp; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

10.  Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products.

Authors:  Narkunaraja Shanmugam; Marpadga A Reddy; Rama Natarajan
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.